Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Terminated 2Active not recruiting 2Unknown 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Skin Neoplasms 6Neoplasms 6Melanoma 5Squamous Cell Carcinoma of Head and Neck 4Carcinoma, Squamous Cell 4Neoplasm Metastasis 3Prostatic Neoplasms 2Lung Neoplasms 2Colonic Neoplasms 2Carcinoma, Merkel Cell 2Advanced Non-Small Cell Lung Cancer 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Sarcoma 1Resectable Non-small Cell Lung Cancer 1Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Multiple Myeloma 1Mouth Neoplasms 1Motor Activity 1Liposarcoma 1Laryngeal Neoplasms 1Kidney Neoplasms 1

Interventions

avelumab 7Nivolumab 5pembrolizumab 4Specimen Handling 3Ipilimumab 3Biopsy 3cemiplimab 2atezolizumab 2Radiotherapy 2Magnetic Resonance Spectroscopy 2tocilizumab 1talimogene laherparepvec 1prednylidene 1poly ICLC 1lutetium Lu 177 dotatate 1lenvatinib 1fludarabine phosphate 1fludarabine 1flt3 ligand protein 1durvalumab 1deltacortene 1Tacrolimus 1Saline Solution 1Radiosurgery 1Radiation 1Prednisone 1MAPRE1 protein, human 1Lutetium-177 1Immunoglobulin G 1Immune Checkpoint Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Merkel Cell × cemiplimab × Clear all
NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Active not recruiting
22 enrolled
Dermatologic

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

NCT05864144 2025-08-15

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Sensei Biotherapeutics, Inc.

Phase 1/2 Active not recruiting
98 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡